7L87
| BG505 SOSIP MD39 in complex with the polyclonal Fab pAbC-2 from animal Rh.32034 (Wk26 time point) | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, BG505 SOSIP MD39 - gp120, ... | Authors: | Antanasijevic, A, Sewall, L.M, Yang, Y.R, Perrett, H.R, Ward, A.B. | Deposit date: | 2020-12-31 | Release date: | 2021-08-04 | Last modified: | 2021-11-24 | Method: | ELECTRON MICROSCOPY (3.6 Å) | Cite: | Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nat Commun, 12, 2021
|
|
7L8F
| BG505 SOSIP.v5.2(7S) in complex with the polyclonal Fab pAbC-2 from animal Rh.33172 (Wk38 time point) | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope glycoprotein gp160, ... | Authors: | Antanasijevic, A, Sewall, L.M, Ward, A.B. | Deposit date: | 2020-12-31 | Release date: | 2021-08-04 | Last modified: | 2021-09-08 | Method: | ELECTRON MICROSCOPY (3.66 Å) | Cite: | Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nat Commun, 12, 2021
|
|
7LOP
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3022 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CR3022 Fab heavy chain, CR3022 Fab light chain, ... | Authors: | Yuan, M, Zhu, X, Wilson, I.A. | Deposit date: | 2021-02-10 | Release date: | 2021-03-03 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.246 Å) | Cite: | Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science, 373, 2021
|
|
7LM8
| |
7LM9
| Crystal structure of SARS-CoV spike protein receptor-binding domain in complex with a cross-neutralizing antibody CV38-142 Fab isolated from COVID-19 patient | Descriptor: | 1,2-ETHANEDIOL, CV38-142 Fab heavy chain, CV38-142 Fab light chain, ... | Authors: | Liu, H, Yuan, M, Zhu, X, Wilson, I.A. | Deposit date: | 2021-02-05 | Release date: | 2021-03-31 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (1.53 Å) | Cite: | A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host Microbe, 29, 2021
|
|
7NAB
| Crystal structure of human neutralizing mAb CV3-25 binding to SARS-CoV-2 S MPER peptide 1140-1165 | Descriptor: | CITRIC ACID, CV3-25 Fab Heavy Chain, CV3-25 Fab Light Chain, ... | Authors: | Chen, Y, Tolbert, W.D, Pazgier, M. | Deposit date: | 2021-06-21 | Release date: | 2021-12-08 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2.15 Å) | Cite: | Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. Cell Rep, 38, 2022
|
|
4JPW
| Crystal structure of broadly and potently neutralizing antibody 12a21 in complex with hiv-1 strain 93th057 gp120 mutant | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID, HEAVY CHAIN OF ANTIBODY 12A21, ... | Authors: | Acharya, P, Luongo, T, Zhou, T, Kwong, P.D. | Deposit date: | 2013-03-19 | Release date: | 2013-04-17 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (2.904 Å) | Cite: | Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell(Cambridge,Mass.), 153, 2013
|
|